TU-E-BRB-03: Biological Dose Optimization for SBRT of Lung Cancer: One Size Does Not Fit All.
Given the differences in tumor size and location, encountered in lung SBRT, we hypothesize that 'one dose fractionation regimen does not fit all', i.e. that there is a role for patient-specific dose prescription based on optimization of biological models. Sixty one NSCLC patients (tumor volume 46.5+/-47.3 cc) treated with stereotactic body radiotherapy (48 Gy in 4fx) were retrospectively studied. Clinically treated plans were generated using Brainlab's Pencil Beam (PB-BL), and then recalculated with fixed MUs using Anisotropic Analytic Algorithm (AAA), Pencil Beam (PB-EC), Monte Carlo (MC) and Collapsed-Cone-Convolution (CCC). DVHs were exported to calculate TCP (Poisson) and NTCP (Lyman-Kutcher-Burman). TCP/NTCP model parameters were utilized from published data. For each dose distribution two dose response curves were generated by scaling the prescription dose and assuming a linear relationship between the prescription dose and entire 3D dose distribution. In addition, associations were assessed between changes in each algorithm's TCP relative to PB-BL, target diameter, and local density (density of the 70% isodose covering the PTV). For PB-BL, mean TCP was 99.6%±0.9%, whereas for same MUs, mean TCP for PB-EC, AAA, CC and MC plans were 96.5±14.3%, 74.6±31.6%, 74.4±32.4% and 76.8±32.0%, respectively. With the same prescription dose for all plans, TCP values changed to 98.1±8.7%, 96.5±15.3%, 77.5±28.6%, 85.4±25.8% and 92.9±20.1% for PB-BL, PB-EC, AAA, and CCC, MC, respectively, indicating that AAA and CCC dose distributions are likely less homogeneous relative to MC. The TCP improvement was 12.3%, 8.9% and 4.4% for AAA, CCC and MC-based plans when the average NTCP before optimization was set as the upper limit for lung toxicity. This work supports patient-specific dose prescription strategies, based on biological optimization, for lung SBRT. However, further investigation is warranted. Acknowledgement: supported in part by a grant from Varian Medical Systems.